Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

Open in Screener

TFFP

Tff Pharmaceuticals Inc

May 14 • 04:00PM ET

1.86

Dollar change +0.05
Percentage change 2.76	%

Healthcare • Biotechnology • USA • NASD

Chart Stock Detail • Compare Perf. • Revenue • Dividends • Options Options Chain • Save to Portfolio • Create Alert

Held by: VTI VXF

Index	-	P/E	-	EPS (ttm)	-12.68	Insider Own	7.13%	Shs Outstand	3.10M	Perf Week	-15.45%
Market Cap	5.77M	Forward P/E	-	EPS next Y	-5.11	Insider Trans	0.00%	Shs Float	2.88M	Perf Month	-47.16%
Income	-21.24M	PEG	-	EPS next Q	-1.51	Inst Own	12.42%	Short Float	4.30%	Perf Quarter	-71.65%
Sales	0.00M	P/S	-	EPS this Y	54.77%	Inst Trans	9.61%	Short Ratio	3.25	Perf Half Y	-67.11%
Book/sh	4.04	P/B	0.46	EPS next Y	4.66%	ROA	-117.54%	Short Interest	0.12M	Perf Year	-89.52%
Cash/sh	1.77	P/C	1.05	EPS next 5Y	-	ROE	-130.94%	52W Range	1.54 - 17.50	Perf YTD	-73.50%
Dividend Est.	-	P/FCF	-	EPS past 5Y	-13.86%	ROI	-221.31%	52W High	-89.37%	Beta	1.38
Dividend TTM	-	Quick Ratio	3.13	Sales past 5Y	0.00%	Gross Margin	-	52W Low	20.78%	ATR (14)	0.45
Dividend Ex-Date	-	Current Ratio	3.13	EPS Y/Y TTM	56.46%	Oper. Margin	0.00%	RSI (14)	26.27	Volatility	16.05% 15.26%
Employees	19	Debt/Eq	0.01	Sales Y/Y TTM	-	Profit Margin	-	Recom	1.00	Target Price	24.50
Option/Short	No / Yes	LT Debt/Eq	0.00	EPS Q/Q	60.48%	Payout	-	Rel Volume	0.86	Prev Close	1.81
Sales Surprise	103.30%	EPS Surprise	-6.19%	Sales Q/Q	-	Earnings	May 14 AMC	Avg Volume	38.08K	Price	1.86
SMA20	-28.91%	SMA50	-62.77%	SMA200	-73.76%	Trades		Volume	32,717	Change	2.76%

Date	Action	Analyst	Rating Change	Price Target Change
May-19-22	Resumed	H.C. Wainwright	Buy	$22
Feb-08-21	Initiated	H.C. Wainwright	Buy	$31
Dec-07-20	Initiated	B. Riley Securities	Buy	$36
Aug-17-20	Reiterated	Maxim Group	Buy	$12 → $18
Jul-08-20	Initiated	Maxim Group	Buy	$12

Today 06:00PM	TFF Pharmaceuticals, Inc. (TFFP) Reports Q1 Loss, Tops Revenue Estimates (Zacks)
04:05PM	TFF Pharmaceuticals Reports First Quarter Financial Results and Provides Corporate Update (GlobeNewswire)
May-01-24 05:07PM	TFF Pharmaceuticals Announces Closing of Pricing of $4.8 Million Public Offering (GlobeNewswire)
Apr-30-24 05:53AM	TFF Pharmaceuticals Prices $4.8 Million Public Offering; Shares Down Pre-Bell (MT Newswires)
Apr-29-24 08:00PM	TFF Pharmaceuticals Announces Pricing of $4.8 Million Public Offering (GlobeNewswire) -7.24%
10:00AM	Loading…
10:00AM	TFF Pharmaceuticals Makes Available Phase 2 Data from Tacrolimus Inhalation Powder (TFF TAC) for the Prevention of Lung Transplant Rejection Presented at the Recent ISHLT Annual Meeting (GlobeNewswire)
Apr-15-24 07:00AM	TFF Pharmaceuticals Announces Additional Positive Data from the Tacrolimus Inhalation Powder (TFF TAC) Phase 2 Trial Following Oral Presentation at the ISHLT 44th Annual Late Breaking Clinical Science Abstract Sessions (GlobeNewswire) -8.57%
Mar-28-24 10:54PM	TFFP Stock Earnings: TFF Pharmaceuticals Beats EPS, Beats Revenue for Q4 2023 (InvestorPlace) -8.35%
04:05PM	TFF Pharmaceuticals Reports Fourth Quarter and Full Year 2023 Financial Results (GlobeNewswire)
Mar-27-24 04:01PM	TFF Pharmaceuticals Announces Updated Data from the Tacrolimus Inhalation Powder (TFF TAC) and Voriconazole Inhalation Powder (TFF VORI) Clinical Programs (GlobeNewswire)
Mar-25-24 09:01AM	TFF Pharmaceuticals Announces Oral Presentation of Interim Data from the Phase 2 Study of Tacrolimus Inhalation Powder (TFF TAC) for the Prevention of Lung Transplant Rejection at the 44th Annual International Society for Heart and Lung Transplantation (ISHLT) 2024 Meeting (GlobeNewswire)
Mar-22-24 03:11PM	TFF Pharmaceuticals Announces Closing of $1.2 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules (GlobeNewswire) -6.33%
Mar-20-24 12:00PM	TFF Pharmaceuticals Announces $1.2 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules (GlobeNewswire) -10.37%
09:03AM	TFF Pharmaceuticals Announces Update on Clinical Programs (GlobeNewswire)
Mar-14-24 04:47PM	TFF Pharmaceuticals to Participate in the 36th Annual Roth Conference March 17-19, 2024 (GlobeNewswire)
08:00AM	Loading…
Jan-24-24 08:00AM	TFF Pharmaceuticals to Present Data from Phase 2 Trial of Voriconazole Inhalation Powder (TFF VORI) for the Treatment of Invasive Pulmonary Aspergillosis at the 11th Advances Against Aspergillosis & Mucormycosis Conference (GlobeNewswire) +10.88%
Jan-09-24 08:00AM	TFF Pharmaceuticals Announces Acceptance of Late-Breaking Abstract for Presentation at the 44th Annual International Society for Heart and Lung Transplantation (ISHLT) 2024 Meeting (GlobeNewswire)
Dec-20-23 10:52AM	TFFP Stock Earnings: TFF Pharmaceuticals Beats EPS, Misses Revenue for Q1 2023 (InvestorPlace) +6.84%
10:52AM	TFFP Stock Earnings: TFF Pharmaceuticals Beats EPS, Beats Revenue for Q2 2023 (InvestorPlace)
Dec-19-23 06:00AM	TFF Pharmaceuticals Announces Positive Initial Data from Ongoing Phase 2 Trials of TFF VORI and TFF TAC (GlobeNewswire) -8.63%
Dec-18-23 04:01PM	TFF Pharmaceuticals to Host Webcast and Conference to Review Initial Data from the Ongoing Phase 2 Trials of TFF VORI and TFF TAC (GlobeNewswire)
Dec-15-23 07:00AM	TFF Pharmaceuticals Announces Reverse Stock Split (GlobeNewswire) -14.28%
Dec-13-23 08:00AM	TFF Pharmaceuticals Appoints Thomas B. King to Board of Directors (GlobeNewswire)
Nov-30-23 08:00AM	TFF Pharmaceuticals Appoints Michael Patane, Ph.D., to Board of Directors (GlobeNewswire) +15.48%
08:00AM	TFF Pharmaceuticals Appoints Catherine Lee, J.D. to Board of Directors (GlobeNewswire)
Nov-27-23 07:00AM	TFF Pharmaceuticals to Participate in the 2023 Benchmark Discovery One-on-One Investor Conference December 7, 2023 (GlobeNewswire)
Nov-16-23 08:37AM	TFF Pharmaceuticals, Inc. (NASDAQ:TFFP) Q3 2023 Earnings Call Transcript (Insider Monkey)
Nov-14-23 04:05PM	TFF Pharmaceuticals Reports Third Quarter 2023 Financial Results and Provides Corporate Update (GlobeNewswire) +8.14%
Nov-08-23 04:05PM	TFF Pharmaceuticals Announces Publication of Data Demonstrating Feasibility of Intranasal Delivery of Monoclonal Antibodies with Thin Film Freezing (GlobeNewswire) -9.85%
Nov-07-23 04:05PM	TFF Pharmaceuticals to Hold Third Quarter 2023 Financial and Business Results Conference Call on November 14, 2023 (GlobeNewswire) -6.05%
05:00PM	Loading…
Oct-02-23 05:00PM	TFF Pharmaceuticals Congratulates our Scientific Advisory Board Member, Drew Weissman, M.D., Ph.D., for Receiving the Nobel Prize in Physiology or Medicine for his Pioneering Work Enabling the Development of mRNA COVID-19 Vaccines (GlobeNewswire)
Sep-28-23 04:29PM	TFF Pharmaceuticals to Participate in Upcoming Investor Conferences (GlobeNewswire)
Aug-23-23 07:00AM	TFF Pharmaceuticals to Participate in the H.C. Wainwright 25th Annual Global Investment Conference September 11-13, 2023 (GlobeNewswire) -5.33%
Aug-17-23 04:01PM	TFF Pharmaceuticals Announces Closing of $5.7 Million Public Offering of Common Stock, Including Full Exercise of Over-Allotment Option (GlobeNewswire)
06:36AM	TFF Pharmaceuticals, Inc. (NASDAQ:TFFP) Q2 2023 Earnings Call Transcript (Insider Monkey)
Aug-16-23 04:25AM	Q2 2023 TFF Pharmaceuticals Inc Earnings Call (Thomson Reuters StreetEvents) -9.76%
Aug-15-23 06:05AM	TFF Pharmaceuticals Reports Second Quarter 2023 Financial Results and Provides Corporate Update (GlobeNewswire) -8.89%
06:00AM	TFF Pharmaceuticals Prices $5 Million Public Offering of Common Stock (GlobeNewswire)
Aug-14-23 04:01PM	TFF Pharmaceuticals Announces Proposed Public Offering of Common Stock (GlobeNewswire) +8.43%
Aug-09-23 08:30AM	TFF Pharmaceuticals to Hold Second Quarter 2023 Financial and Business Results Conference Call on August 15, 2023 (GlobeNewswire)
Aug-08-23 05:50PM	Iovance Biotherapeutics (IOVA) Reports Q2 Loss, Lags Revenue Estimates (Zacks)
Jul-31-23 07:00AM	TFF Pharmaceuticals Inc. and Uniphar Durbin Ireland Ltd. Announce the Opening of an Expanded Access Program for Voriconazole Inhalation Powder (TFF VORI) for the Treatment of Pulmonary Aspergillosis and Other Voriconazole Responsive Fungal Pulmonary Infections (GlobeNewswire) +11.37%
Jun-26-23 07:00AM	TFF Pharmaceuticals Awarded $2.97 Million to Develop Universal Influenza Vaccine (GlobeNewswire)
May-23-23 04:05PM	TFF Pharmaceuticals to Participate in the 2023 Jefferies Healthcare Conference (GlobeNewswire)
May-11-23 04:05PM	TFF Pharmaceuticals Provides Corporate Update and Reports First Quarter 2023 Financial Results (GlobeNewswire)
May-09-23 07:15AM	Sidoti's Micro-Cap Virtual May Conference (ACCESSWIRE)
May-04-23 08:00AM	TFF Pharmaceuticals Enters into CRADA with the National Institute of Environmental Health Sciences to Develop Dry Powder Formulations of Hyaluronan to Prevent and Treat Respiratory Diseases (GlobeNewswire) +15.64%
May-01-23 07:00AM	TFF Pharmaceuticals Receives Additional Funding from Leidos to Advance Next-Generation Personalized Protective Biosystems under the DARPA PPB Program (GlobeNewswire)
Apr-08-23 08:58AM	We're A Little Worried About TFF Pharmaceuticals' (NASDAQ:TFFP) Cash Burn Rate (Simply Wall St.)
Mar-07-23 04:15PM	TFF Pharmaceuticals Reports Fourth Quarter 2022 and Full Year 2022 Financial Results (GlobeNewswire)
Mar-06-23 04:05PM	TFF Pharmaceuticals to Participate in the 35th Annual Roth Conference (GlobeNewswire)
Feb-23-23 01:01PM	3 Bargain Stocks Worth Buying at These 52-Week Lows (InvestorPlace) +17.36%
Feb-08-23 04:05PM	TFF Pharmaceuticals Appoints Harlan Weisman, M.D. as Permanent Chief Executive Officer (GlobeNewswire)
Jan-09-23 08:00AM	TFF Pharmaceuticals Announces the Appointment of Zamaneh Mikhak, M.D. as Chief Medical Officer (GlobeNewswire)
Dec-05-22 06:30AM	TFF Pharmaceuticals Announces Leadership Transition (GlobeNewswire)
Nov-29-22 04:01PM	TFF Pharmaceuticals Announces Closing of $12.3 Million Public Offering (GlobeNewswire)
Nov-21-22 01:40PM	15 Most Volatile Stocks to Buy Now (Insider Monkey) +5.98%
Nov-18-22 08:00AM	TFF Pharmaceuticals Prices $10.675 Million Offering of Common Stock and Warrants (GlobeNewswire) -9.30%
Nov-17-22 04:01PM	TFF Pharmaceuticals Announces Proposed Public Offering of Common Stock and Warrants (GlobeNewswire)
05:34AM	TFF Pharmaceuticals Third Quarter 2022 Earnings: US$0.29 loss per share (vs US$0.34 loss in 3Q 2021) (Simply Wall St.)
Nov-14-22 04:01PM	TFF Pharmaceuticals Reports Third Quarter 2022 Financial Results and Provides Business Update (GlobeNewswire) -12.43%
Nov-07-22 04:05PM	TFF Pharmaceuticals to Hold Third Quarter 2022 Financial and Business Results Conference Call on November 14, 2022 (GlobeNewswire) -11.67%
Nov-03-22 08:00AM	TFF Pharmaceuticals Announces Collaboration with Aptar Pharma to Explore and Develop Intranasal Delivery of Dry Powder Vaccines and Dry Powder Therapeutics (GlobeNewswire) +14.94%
Nov-02-22 12:47PM	Why TFF Pharmaceuticals Shares Are Sinking Today? (Benzinga) -35.56%
Nov-01-22 04:07PM	TFF Pharmaceuticals Announces Second Patient Successfully Treated with Voriconazole Inhalation Powder Through Compassionate Use Program (GlobeNewswire) +8.00%
04:05PM	TFF Pharmaceuticals Announces Program Updates for Voriconazole Inhaled Powder and Tacrolimus Inhaled Powder Clinical Programs (GlobeNewswire)
Oct-18-22 10:23AM	Is TFF Pharmaceuticals (NASDAQ:TFFP) In A Good Position To Deliver On Growth Plans? (Simply Wall St.)
Oct-11-22 08:00AM	TFF Pharmaceuticals Announces Presentation of Data Featuring Applications of Thin Film Freezing Technology at AAPS PharmSci 360 Meeting (GlobeNewswire)
Sep-26-22 08:00AM	TFF Pharmaceuticals to Participate in the Roth Inaugural Healthcare Opportunities Conference (GlobeNewswire) -5.15%
Sep-22-22 08:00AM	TFF Pharmaceuticals Announces Acceptance of Multiple Abstracts Featuring Applications of Thin Film Freezing Technology at the Upcoming AAPS PharmSci 360 Meeting (GlobeNewswire)
Sep-08-22 08:00AM	TFF Pharmaceuticals Announces Presentation of Patient Data with Voriconazole Inhalation Powder (TFF VORI) at the 15th International Congress on Lung Transplantation (GlobeNewswire) +13.60%
Sep-06-22 08:00AM	TFF Pharmaceuticals to Participate at The H.C. Wainwright 24th Annual Global Investment Conference (GlobeNewswire)
Aug-12-22 11:30AM	TFF Pharmaceuticals, Inc. (TFFP) Q2 2022 Earnings Call Transcript (Motley Fool)
Aug-11-22 04:05PM	TFF Pharmaceuticals Reports Second Quarter 2022 Financial Results and Provides Business Update (GlobeNewswire)
Aug-02-22 04:05PM	TFF Pharmaceuticals to Hold Second Quarter 2022 Financial and Business Results Conference Call on August 11, 2022 (GlobeNewswire) +6.09%
Jul-14-22 08:00AM	TFF Pharmaceuticals Expands R&D Operations with New Austin Facility (GlobeNewswire)
Jun-24-22 03:44PM	TFF Pharmaceuticals, Inc. (NASDAQ:TFFP) Is Expected To Breakeven In The Near Future (Simply Wall St.)
Jun-09-22 08:00AM	TFF Pharmaceuticals to Participate at The JMP Securities Life Sciences Conference (GlobeNewswire)
Jun-01-22 08:00AM	TFF Pharmaceuticals to Participate at the Jefferies Healthcare Conference (GlobeNewswire)
May-31-22 09:55AM	Wall Street Analysts Think TFF Pharmaceuticals, Inc. (TFFP) Could Surge 233%: Read This Before Placing a Bet (Zacks) -7.24%
May-20-22 09:32AM	TFF Pharmaceuticals to Participate at the H.C. Wainwright Global Investment Conference (GlobeNewswire)
May-11-22 05:15PM	TFF Pharmaceuticals, Inc. (TFFP) Reports Q1 Loss, Misses Revenue Estimates (Zacks) -5.00%
04:01PM	TFF Pharmaceuticals Reports First Quarter 2022 Financial Results and Provides Business Update (GlobeNewswire)
May-10-22 03:34PM	Is TFF Pharmaceuticals (NASDAQ:TFFP) In A Good Position To Invest In Growth? (Simply Wall St.)
May-02-22 08:00AM	TFF Pharmaceuticals Announces Multiple Presentations Highlighting Broad Applicability of its Thin Film Freezing Technology at Respiratory Drug Delivery Meeting (RDD) (GlobeNewswire)
Apr-29-22 07:30AM	TFF Pharmaceuticals to Hold First Quarter 2022 Financial and Business Results Conference Call on May 11, 2022 (GlobeNewswire)
Apr-28-22 08:04AM	Adicet Bio, Inc. (ACET) Surges 6.8%: Is This an Indication of Further Gains? (Zacks)
Apr-19-22 08:00AM	TFF Pharmaceuticals Announces Safety and Pharmacokinetic Data from Phase 1 Study of Niclosamide Inhalation Powder (GlobeNewswire)
Apr-05-22 09:09PM	2 Stocks Under $10 That This Insider Is Aggressively Buying (TipRanks)
Mar-25-22 12:00AM	TFF Pharmaceuticals, Inc. (TFFP) Q4 2021 Earnings Call Transcript (Motley Fool)
Mar-24-22 05:45PM	TFF Pharmaceuticals, Inc. (TFFP) Reports Q4 Loss, Lags Revenue Estimates (Zacks)
04:26PM	TFF Pharmaceuticals Reports Fourth Quarter and Full Year 2021 Financial Results and Provides Business Update (GlobeNewswire)
Mar-17-22 11:07AM	TFF Pharma Inks Research Pact With US Army For Dry Powder Medical Countermeasures (Benzinga) +7.49%
08:00AM	TFF Pharmaceuticals Enters into CRADA with the U.S. Army and The Geneva Foundation to Develop Dry Powder Needle-free Medical Countermeasures (GlobeNewswire)
Mar-11-22 07:05AM	TFF Pharmaceuticals to Participate at the 34th Annual Roth Conference (GlobeNewswire)
Mar-09-22 04:05PM	TFF Pharmaceuticals to Hold Fourth Quarter and Full Year 2021 Financial and Business Results Conference Call on March 24, 2022 (GlobeNewswire) +6.53%
Mar-07-22 10:16AM	Catalent's (CTLT) New Tie-Up to Provide Better Patient Access (Zacks) -9.10%
Mar-01-22 08:00AM	TFF Pharmaceuticals and Catalent Announce New Inhalation Dry Powder Development and Manufacturing Agreement (GlobeNewswire)
Feb-24-22 02:29PM	TFF Pharma's Inhaled Niclosamide Shows Potent Activity Against Omicron Variant (Benzinga) +10.14%
09:27AM	TFF Pharmaceuticals Announces Inhaled Niclosamide Significantly Inhibits Viral Replication of the Omicron Variant of SARS-CoV-2 (GlobeNewswire)

TFF Pharmaceuticals, Inc. engages in the development and commercialization of drug products based on its patented Thin Film Freezing technology platform. It focuses on the manufacture of inhaled dry powder drugs for the treatment of pulmonary diseases and conditions. The company was founded on January 24, 2018 and is headquartered in Fort Worth, TX.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
CARLSON CAPITAL L P	10% Owner	Aug 16 '23	Sale	0.39	1,000	392	5,064,000	Aug 17 05:29 PM
Weisman Harlan F	President and CEO	Aug 15 '23	Buy	0.25	600,000	150,000	814,615	Aug 15 08:00 AM
Mikhak Zamaneh	Chief Medical Officer	Aug 15 '23	Buy	0.25	120,000	30,000	135,000	Aug 15 08:00 AM
MILLS ROBERT S	Director	Aug 15 '23	Buy	0.25	40,000	10,000	55,980	Aug 15 08:00 AM
COLEMAN KIRK ALLEN	Chief Financial Officer	Aug 15 '23	Buy	0.25	20,000	5,000	35,675	Aug 15 08:00 AM
Roberts Brandi	Director	Aug 15 '23	Buy	0.25	20,000	5,000	20,000	Aug 15 08:00 AM
ROCAMBOLI STEPHEN	Director	Aug 15 '23	Buy	0.25	20,000	5,000	36,000	Aug 15 08:00 AM
CARLSON CAPITAL L P	10% Owner	Aug 15 '23	Sale	0.44	215,000	94,041	5,065,000	Aug 17 05:29 PM

Dollar change -0.05
Percentage change -2.24	%

ESPR Esperion Therapeutics Inc. daily Stock Chart

Held by: VTI VXF ITOT IWC JFWD AVUS QQQS

Index	-	P/E	-	EPS (ttm)	-1.01	Insider Own	1.10%	Shs Outstand	170.42M	Perf Week	-8.02%
Market Cap	371.52M	Forward P/E	10.70	EPS next Y	0.20	Insider Trans	0.00%	Shs Float	168.54M	Perf Month	12.66%
Income	-86.51M	PEG	-	EPS next Q	-0.18	Inst Own	51.10%	Short Float	11.79%	Perf Quarter	-14.17%
Sales	229.74M	P/S	1.62	EPS this Y	97.29%	Inst Trans	5.01%	Short Ratio	2.81	Perf Half Y	140.83%
Book/sh	-1.57	P/B	-	EPS next Y	470.58%	ROA	-27.69%	Short Interest	19.87M	Perf Year	41.56%
Cash/sh	1.33	P/C	1.64	EPS next 5Y	16.90%	ROE	-	52W Range	0.70 - 3.40	Perf YTD	-27.09%
Dividend Est.	-	P/FCF	-	EPS past 5Y	23.09%	ROI	-41.48%	52W High	-35.88%	Beta	1.00
Dividend TTM	-	Quick Ratio	1.78	Sales past 5Y	7.64%	Gross Margin	81.82%	52W Low	211.43%	ATR (14)	0.21
Dividend Ex-Date	-	Current Ratio	2.22	EPS Y/Y TTM	71.60%	Oper. Margin	-9.40%	RSI (14)	50.02	Volatility	8.43% 8.74%
Employees	240	Debt/Eq	-	Sales Y/Y TTM	183.74%	Profit Margin	-37.65%	Recom	1.75	Target Price	7.41
Option/Short	Yes / Yes	LT Debt/Eq	-	EPS Q/Q	140.90%	Payout	-	Rel Volume	0.65	Prev Close	2.23
Sales Surprise	64.10%	EPS Surprise	598.15%	Sales Q/Q	466.14%	Earnings	May 07 BMO	Avg Volume	7.06M	Price	2.18
SMA20	6.94%	SMA50	-4.57%	SMA200	19.58%	Trades		Volume	4,567,477	Change	-2.24%

Date	Action	Analyst	Rating Change	Price Target Change
Jan-03-24	Downgrade	BofA Securities	Buy → Neutral
Nov-20-23	Resumed	JP Morgan	Neutral
Aug-01-23	Upgrade	Northland Capital	Under Perform → Market Perform
Jun-15-23	Upgrade	BofA Securities	Underperform → Buy	$1.25 → $4
Mar-16-23	Downgrade	Northland Capital	Market Perform → Under Perform	$1
Mar-16-23	Downgrade	BofA Securities	Neutral → Underperform	$8 → $1.50
Mar-07-23	Upgrade	Credit Suisse	Underperform → Neutral	$6.50 → $7
Feb-27-23	Resumed	BofA Securities	Neutral	$8
Feb-24-23	Upgrade	Jefferies	Hold → Buy	$12
Feb-03-23	Upgrade	Morgan Stanley	Underweight → Equal-Weight	$9
Aug-03-22	Downgrade	Credit Suisse	Neutral → Underperform	$7 → $6
May-05-22	Upgrade	JP Morgan	Underweight → Neutral	$6
Mar-10-22	Initiated	H.C. Wainwright	Buy	$22
Oct-19-21	Downgrade	Credit Suisse	Outperform → Neutral	$28 → $11
Oct-14-21	Downgrade	Morgan Stanley	Equal-Weight → Underweight	$17 → $11
May-05-21	Downgrade	Stifel	Buy → Hold	$37 → $20
Apr-26-21	Resumed	Credit Suisse	Outperform	$45
Mar-11-21	Initiated	Morgan Stanley	Equal-Weight	$30
Feb-12-21	Downgrade	Jefferies	Buy → Hold	$30
Feb-09-21	Downgrade	Goldman	Neutral → Sell	$44 → $24

Show Previous Ratings

Today 08:00AM	Esperion Receives Five Year Patent Extension for Bempedoic Acid, Contained in NEXLETOL and NEXLIZET (GlobeNewswire)
May-10-24 04:00PM	Esperion Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) (GlobeNewswire)
May-08-24 12:20PM	Esperion (ESPR) Q1 Earnings Beat, Stock Up on Strong Revenues (Zacks) -13.92%
11:08AM	Esperion Therapeutics, Inc. (NASDAQ:ESPR) Q1 2024 Earnings Call Transcript (Insider Monkey)
03:04AM	Esperion Therapeutics Inc (ESPR) Q1 2024 Earnings Call Transcript Highlights: Soaring Revenues ... (GuruFocus.com)
12:20PM	Loading…
May-07-24 12:20PM	Heart Disease Drugmaker Esperion Therapeutics Reports Highest Revenue Yet, Stock Soars (Benzinga) +11.79%
10:55AM	ESPR Stock Earnings: Esperion Therapeutics Beats EPS, Beats Revenue for Q1 2024 (InvestorPlace)
08:55AM	Esperion Therapeutics Inc (ESPR) Surpasses Q1 Revenue Forecasts with a 467% Increase (GuruFocus.com)
08:22AM	Why Is Esperion Therapeutics (ESPR) Stock Up 13% Today? (InvestorPlace)
07:39AM	Today's Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Tuesday (InvestorPlace)
07:36AM	Top Premarket Gainers (MT Newswires)
07:15AM	Esperion Therapeutics (ESPR) Q1 Earnings and Revenues Beat Estimates (Zacks)
06:11AM	Esperion Therapeutics: Q1 Earnings Snapshot (Associated Press Finance)
06:00AM	Esperion Reports First Quarter 2024 Financial Results (GlobeNewswire)
Apr-29-24 08:00AM	Esperion to Participate in Upcoming May Investor Conferences (GlobeNewswire)
08:00AM	Loading…
Apr-23-24 08:00AM	Esperion to Report First Quarter 2024 Financial Results on May 7 (GlobeNewswire) +9.42%
Apr-21-24 10:39AM	11 Best Low Price Pharma Stocks To Invest In (Insider Monkey)
Apr-07-24 02:45PM	Esperion Presents Important New Data from CLEAR Outcomes at ACC.24 Highlighting Value of NEXLETOL (bempedoic acid) Tablets in Diverse Populations Including Women, Hispanics/Latinx and Patients with Obesity (GlobeNewswire)
Apr-01-24 08:00AM	Esperion to Ring Nasdaq Opening Bell Today, April 1, 2024 (GlobeNewswire)
Mar-28-24 11:30AM	Why Is Esperion Therapeutics (ESPR) Up 2% Since Last Earnings Report? (Zacks)
Mar-26-24 08:00AM	Esperion to Participate in 23rd Annual Needham Virtual Healthcare Conference (GlobeNewswire)
Mar-25-24 04:00PM	Esperion Announces Data from CLEAR Outcomes Sub-Groups as Poster Presentations, Moderated Session & Industry Expert Theatre to be Presented at ACC.24 (GlobeNewswire) +14.41%
Mar-22-24 06:26PM	U.S. FDA Approves Broad New Labels for Esperion's NEXLETOL and NEXLIZET to Prevent Heart Attacks and Cardiovascular Procedures in Both Primary and Secondary Prevention Patients, Regardless of Statin Use (Business Wire) +8.53%
03:10PM	U.S. FDA Approves Broad New Labels for NEXLETOL and NEXLIZET to Prevent Heart Attacks and Cardiovascular Procedures in Both Primary and Secondary Prevention Patients, Regardless of Statin Use (GlobeNewswire)
11:04AM	CHMP Issues Positive Opinions For Both Bempedoic Acid And The Bempedoic Acid / Ezetimibe Fixed-Dose Combination Tablet As Treatments For Hypercholesterolemia And Significantly Reducing Cardiovascular Events (GlobeNewswire)
Mar-04-24 08:28PM	11 Best Small Cap Pharma Stocks to Invest In (Insider Monkey)
Feb-28-24 08:34AM	Esperion Therapeutics, Inc. (NASDAQ:ESPR) Q4 2023 Earnings Call Transcript (Insider Monkey) -11.38%
07:41AM	Esperion (ESPR) Q4 Earnings Top, Stock Up on Strong Revenues (Zacks)
Feb-27-24 09:38PM	Q4 2023 Esperion Therapeutics Inc Earnings Call (Thomson Reuters StreetEvents) +10.27%
07:53AM	Esperion Therapeutics Inc (ESPR) Reports Strong Revenue Growth in Q4 and FY 2023 (GuruFocus.com)
07:20AM	Loading…
07:20AM	Esperion Therapeutics (ESPR) Reports Q4 Loss, Tops Revenue Estimates (Zacks)
06:25AM	Esperion Therapeutics: Q4 Earnings Snapshot (Associated Press Finance)
06:00AM	Esperion Reports Fourth Quarter and Full Year 2023 Financial Results (GlobeNewswire)
03:30AM	12 Best Medical Stocks to Buy Under $10 (Insider Monkey)
Feb-16-24 04:30PM	Esperion Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) (GlobeNewswire)
Feb-15-24 03:13AM	Should You Sell Esperion Therapeutics (ESPR)? (Insider Monkey)
Feb-13-24 10:00AM	Esperion Therapeutics (ESPR) Expected to Beat Earnings Estimates: Can the Stock Move Higher? (Zacks)
08:00AM	Esperion to Report Fourth Quarter and Full Year 2023 Financial Results on February 27 (GlobeNewswire)
Feb-01-24 02:00PM	RFK, Esperion Therapeutics Announce 2024 Promotional Schedule (GlobeNewswire)
Jan-23-24 04:00PM	Esperion Announces Closing of Public Offering of Common Stock and Exercise in Full of Underwriters' Option to Purchase Additional Shares (GlobeNewswire)
Jan-19-24 08:50AM	Why Is Esperion Therapeutics (ESPR) Stock Down 24% Today? (InvestorPlace) -6.05%
Jan-18-24 09:15PM	Esperion Announces Pricing of $85.1 Million Public Offering of Common Stock (GlobeNewswire) -16.34%
04:00PM	Esperion Announces Proposed Public Offering of Common Stock (GlobeNewswire)
Jan-03-24 07:00AM	Esperion and Daiichi Sankyo Europe Announce $125 Million Amendment to Their Collaboration, Including Resolution of Pending Litigation (GlobeNewswire) -21.23%
Dec-18-23 08:00AM	Esperion to Participate in 42nd Annual J.P. Morgan Healthcare Conference (GlobeNewswire) +15.93%
Dec-13-23 04:00PM	U.S. FDA Updates LDL-C Lowering Indication for Esperion's NEXLETOL (bempedoic acid) Tablet and NEXLIZET (bempedoic acid and ezetimibe) Tablet (GlobeNewswire)
Dec-07-23 11:30AM	Why Is Esperion Therapeutics (ESPR) Up 51.4% Since Last Earnings Report? (Zacks) +5.33%
Nov-13-23 10:30AM	Esperion Presents CLEAR Outcomes Analysis of Inflammation as Predictor of Cardiovascular Risk at American Heart Association Scientific Sessions 2023 (GlobeNewswire)
Nov-11-23 11:00AM	Partners Announce TRANSFORM Trial to Evaluate Personalized Heart Disease Care Strategies at American Heart Association 2023 (GlobeNewswire)
Nov-09-23 04:30PM	Esperion Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) (GlobeNewswire) -10.79%
Nov-08-23 01:16PM	Esperion (ESPR) Q3 Earnings Beat, Stock Up on Strong Revenues (Zacks)
11:04AM	Esperion Therapeutics, Inc. (NASDAQ:ESPR) Q3 2023 Earnings Call Transcript (Insider Monkey)
Nov-07-23 08:19AM	Esperion Therapeutics Inc (ESPR) Reports 79% Y/Y Growth in Q3 Total Revenue (GuruFocus.com) +7.74%
07:15AM	Esperion Therapeutics (ESPR) Reports Q3 Loss, Tops Revenue Estimates (Zacks)
06:06AM	Esperion Therapeutics: Q3 Earnings Snapshot (Associated Press Finance)
06:00AM	Esperion Reports Third Quarter 2023 Financial Results (GlobeNewswire)
Nov-01-23 10:01AM	Cronos Group (CRON) May Report Negative Earnings: Know the Trend Ahead of Next Week's Release (Zacks)
Oct-31-23 08:00AM	Esperion to Participate in Jefferies London Healthcare Conference (GlobeNewswire)
Oct-24-23 08:00AM	Esperion to Report Third Quarter 2023 Financial Results on November 7 (GlobeNewswire)
Sep-12-23 10:15AM	American College of Cardiology Program to Increase Cholesterol Screenings (GlobeNewswire)
Aug-31-23 11:31AM	Why Is Esperion Therapeutics (ESPR) Down 10.6% Since Last Earnings Report? (Zacks)
Aug-28-23 08:00AM	Esperion to Participate in H.C. Wainwright 25th Annual Global Investment Conference (GlobeNewswire) +14.49%
Aug-26-23 11:00AM	Esperion Presents Two CLEAR Outcomes Study Late-Breakers at European Society of Cardiology Congress 2023 (GlobeNewswire)
Aug-11-23 08:00AM	Two CLEAR Outcomes Study Late-Breakers Accepted at European Society of Cardiology (ESC) Congress 2023 (GlobeNewswire)
Aug-08-23 04:15PM	Esperion Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) (GlobeNewswire)
Aug-06-23 08:06AM	With 77% ownership, Esperion Therapeutics, Inc. (NASDAQ:ESPR) boasts of strong institutional backing (Simply Wall St.)
Aug-02-23 09:06AM	Esperion (ESPR) Q2 Earnings Top, Stock Up on Strong Revenues (Zacks) +5.92%
Aug-01-23 07:15AM	Esperion Therapeutics (ESPR) Reports Q2 Loss, Tops Revenue Estimates (Zacks) +7.64%
06:05AM	Esperion Therapeutics: Q2 Earnings Snapshot (AP Finance)
06:00AM	Esperion Reports Second Quarter 2023 Financial Results (GlobeNewswire)
Jul-24-23 08:00AM	Esperion to Participate in BTIG Virtual Biotechnology Conference 2023 (GlobeNewswire)
Jul-18-23 08:00AM	Esperion to Report Second Quarter 2023 Financial Results on August 1 (GlobeNewswire) +5.37%
Jul-17-23 06:00AM	Esperion to Report Second Quarter 2023 Financial Results on August 1 (GlobeNewswire)
Jul-07-23 08:00AM	Esperion to Present Additional Data from the CLEAR Outcomes Study on CVD Prevention at the American Society for Preventive Cardiology (ASPC) Congress 2023 (GlobeNewswire)
Jun-28-23 08:00AM	Esperion Announces Submission of Application for Expanded Indication with the European Medicines Agency (EMA) for NILEMDO® (bempedoic acid) Tablet and NUSTENDI® (bempedoic acid and ezetimibe) Tablet (GlobeNewswire)
Jun-24-23 02:30PM	Esperion Presents Results from CLEAR Outcomes Primary Prevention Analysis at 83rd American Diabetes Association Scientific Sessions (GlobeNewswire)
Jun-15-23 02:30PM	Esperion Presents Results from New Analysis on Cardiovascular Benefits with Bempedoic Acid Treatment at ENDO 2023 (GlobeNewswire) +11.38%
06:27AM	Not Many Are Piling Into Esperion Therapeutics, Inc. (NASDAQ:ESPR) Stock Yet As It Plummets 28% (Simply Wall St.)
Jun-08-23 11:30AM	Why Is Esperion Therapeutics (ESPR) Down 6.9% Since Last Earnings Report? (Zacks)
08:00AM	Esperion to Present New Key Science at the American Diabetes Associations 83rd Scientific Sessions 2023 (GlobeNewswire)
Jun-07-23 09:54AM	When Will Esperion Therapeutics, Inc. (NASDAQ:ESPR) Turn A Profit? (Simply Wall St.)
Jun-05-23 08:00AM	Esperion to Present Additional Analyses from the Landmark CLEAR Outcomes Study at ENDO 2023 (GlobeNewswire)
Jun-01-23 08:00AM	Esperion Announces Submission of Supplemental New Drug Applications to U.S. FDA for NEXLETOL® (bempedoic acid) Tablet and NEXLIZET® (bempedoic acid and ezetimibe) Tablet (GlobeNewswire)
May-25-23 04:30PM	Esperion Announces Adjournment of 2023 Annual Meeting of Stockholders (GlobeNewswire) -5.70%
May-24-23 08:00AM	Esperion to Participate in Jefferies Healthcare Conference (GlobeNewswire)
May-12-23 04:30PM	Esperion Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) (GlobeNewswire)
May-10-23 09:55AM	Esperion (ESPR) Q1 Earnings Miss Estimates, Sales Beat, Stock Up (Zacks)
May-09-23 08:25AM	Esperion Therapeutics (ESPR) Reports Q1 Loss, Tops Revenue Estimates (Zacks) +5.19%
07:14AM	Esperion Therapeutics: Q1 Earnings Snapshot (AP Finance)
07:00AM	Esperion Reports First Quarter 2023 Financial Results (GlobeNewswire)
May-04-23 08:30AM	Esperion Retains Gibson Dunn to Secure $300 Million Payment From DSE; Will Announce First Quarter Financial Results Tuesday, May 9 (GlobeNewswire)
May-01-23 08:00AM	Esperion to Participate in JMP Securities Life Sciences Conference (GlobeNewswire) +7.58%
Apr-27-23 08:00AM	Esperion to Participate in Bank of America Securities 2023 Health Care Conference (GlobeNewswire)
Apr-25-23 10:01AM	Esperion Therapeutics (ESPR) May Report Negative Earnings: Know the Trend Ahead of Q1 Release (Zacks)
08:00AM	Esperion to Report First Quarter 2023 Financial Results May 9, 2023 (GlobeNewswire)
Apr-19-23 08:42AM	Esperion Announces Co-Promotion Agreement With Currax Pharmaceuticals LLC (GlobeNewswire)
Apr-06-23 05:39PM	7 Very Undervalued Penny Stocks to Buy in April 2023 (InvestorPlace) +7.94%
Apr-03-23 08:00AM	Esperion to Participate in Needham 22nd Annual Virtual Healthcare Conference (GlobeNewswire)
Mar-23-23 11:30AM	Esperion Therapeutics (ESPR) Down 74.3% Since Last Earnings Report: Can It Rebound? (Zacks) +6.85%
Mar-22-23 04:15PM	Esperion Announces Closing of $56.7 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules (GlobeNewswire)

Esperion Therapeutics, Inc. is a pharmaceutical company, which engages in the development and commercialization of oral therapies for elevated low-density lipoprotein cholesterol. The firm offers NEXLETOL (bempedoic acid) tablets, and NEXLIZET (bempedoic acid and ezetimibe) tablets. The company was founded by Roger S. Newton, Hans Ageland, Jan O. Johansson, Anders Paul Wiklund, Michael E. Pape, David I. Scheer and Charles L. Bisgaier in May 1998 and is headquartered in Ann Arbor, MI.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Warren Eric	Chief Commercial Officer	Sep 20 '23	Sale	1.25	742	924	68,318	Sep 21 05:06 PM
Warren Eric	Chief Commercial Officer	Aug 18 '23	Sale	1.41	243	344	69,060	Aug 21 04:32 PM
Warren Eric	Chief Commercial Officer	Jul 19 '23	Sale	1.58	106	168	69,303	Jul 20 04:38 PM
Warren Eric	Chief Commercial Officer	Jun 21 '23	Sale	1.48	603	894	69,409	Jun 22 04:45 PM
Warren Eric	Chief Commercial Officer	May 17 '23	Sale	1.62	219	356	70,012	May 18 04:07 PM

affiliate • advertise • toggle light mode • contact • privacy • help
do not sell my data • privacy settings

TFFP

Tff Pharmaceuticals Inc

ESPR

Esperion Therapeutics Inc.

Upgrade your FINVIZ experience